ABMD
ABIOMED
Abiomed is a publicly-traded medical devices company that develops and manufactures the circulatory support device Impella, the world’s smallest heart pump. The company is headquartered in Danvers, Massachusetts and has three additional offices, two in Germany in the cities of Berlin and Aachen, and another in Tokyo, Japan. Michael R. Minogue is Chairman, CEO & President of the company, with Dr. Thorsten Siess as Chief Technology Officer, Dr. Chuck Simonton as Chief Medical Officer and Dr. David M. Weber as Chief Operating Officer. According to Bloomberg, the company “engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients”. As of 2019, the company had secured five FDA approvals and 715 patents with 622 pending. For fiscal year 2019, Abiomed reported $769.4 million in revenue and reported diluted earnings per share was $5.61 for the year.
Index: NASDAQ; Sector: Healthcare; Industry: Medical Equipment & Supplies;
Marketcap: 12.28B; Volume: 30.81K; AvgVol 3m: 324.99K; Beta: 1.17;
Cost estimate:
P/E: 78.32; EPS: 3.48; EPS growth quarter/prev quarter: -49.20%;
EPS growth this year: -21.00%; EPS growth past 5 years: 10.80%;
EPS ttm: 3.48;
P/S: 14.86; P/B: 10.82; P/Cashflow: 27.75; P/FCF: 49.35;
Sales: 798.06M; Sales growth quarter/prev quarter: -20.60%; Sales growth past 5 years: 29.60%;
Profitability:
Gross Margin: 81.20%; Profit Margin: 19.90%; Operating Margin: 27.30%;
ROA – return on assets: 13.30%; ROE – return on equity: 15.10%; LT Debt/Equity: 0.00; Total Debt/Equity: 0.00;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 1.40%; Insider Transactions:-17.23%;
Institutional Ownership: 98.70%; Institutional Transactions: 0.42%;
Data update: 07.10.2020.